Soleno Therapeutics, Inc. - Common Stock (SLNO)

LOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - March 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) on behalf of investors that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025 (the “Class Period”).

The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Law Offices of Howard G. Smith announces an investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - March 9, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) on behalf of investors that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025 (the “Class Period”).

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) investors concerning the Company’s possible violations of the federal securities laws.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025. Soleno describes itself as a “biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases.”

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”), have until May 5, 2026 to seek appointment as lead plaintiff of the Soleno class action lawsuit. Captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979 (N.D. Cal.), the Soleno class action lawsuit charges Soleno and certain of Soleno’s top executive officers with violations of the Securities Exchange Act of 1934.

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome (“PWS”).

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

The law firm of Kirby McInerney LLP continues its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE:AGL), Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE:AGL), Soleno Therapeutics, Inc. (NASDAQ:SLNO), AVITA Medical, Inc. (NASDAQ:RCEL), and Coty, Inc. (NYSE:COTY). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.